Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Imdelltra, Balversa, 2 More New Drugs Skip March Listing
Four of the 16 new medicines approved in Japan late last year will be taking a pass on the NHI price listing in March, including Amgen’s Imdelltra (tarlatamab) and Janssen Pharmaceutical’s (J&J) Balversa (erdafitinib), Jiho has learned. Jiho compared the…
To read the full story
Related Article
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…